Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs JTX 4014 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jounce Therapeutics
- 28 Dec 2018 Status changed from planning to recruiting.
- 28 Nov 2018 New trial record
- 13 Nov 2018 According to a Jounce Therapeutics media release, the company filed an Investigational New Drug (IND) application for JTX-4014 in September 2018. The U.S. Food and Drug Administration (FDA) approved the IND in October 2018.